• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Hyperfine Receives CE Mark and UKCA Approval for Optive AI™ Software, Expanding Global Commercialization of Latest AI-Powered Imaging Software

    9/2/25 8:15:00 AM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $HYPR alert in real time by email

    Approvals mark a major milestone and bring the most advanced image quality to date to Swoop® system users in European markets

    Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced it has received CE Marking and UK Conformity Assessment (UKCA) approval for its Optive AI™ software. These approvals, which closely follow the US FDA clearance, deliver a substantial leap in image quality for the Swoop® portable MRI system and expand international access to the latest Hyperfine AI-powered imaging software. Together, they mark a pivotal step in the company's ongoing commercial expansion across international markets.

    Optive AI™ software enhances each stage of the imaging process—from noise cancellation and image acquisition to reconstruction and post-processing. The result is brain images with greater clarity, uniformity, and sharper anatomical detail. The software is fully compatible with first-generation Swoop® systems and requires no hardware modifications, enabling current users to benefit from the dramatic AI-driven image quality enhancements.

    "In L'Aquila, over the last few months, we have been leading a project with two other Italian centers to use the Swoop system for stroke triage. The new Optive AI™ software, with the latest AI from Hyperfine, provides a very significant upgrade in image quality and opens additional opportunities to deploy the Swoop® system clinically for easier and more efficient access to MRI in healthcare systems," said Professor Simona Sacco, Head of Neurology at the University of L'Aquila.

    Multiple sites across European markets are already using the Swoop® system to support patient care in pediatric, critical care, stroke, and neurodegenerative settings. Hyperfine will begin deploying Optive AI™ software to current Swoop® system users in the European Economic Area (EEA) and UK in the fourth quarter of 2025, with local language support available at launch.

    "Our research with the Swoop® system thus far aims to develop a more accessible approach to dementia assessment. Furthermore, we are planning to deploy the portable scanner to improve efficiency and reach of MRI in Kent. The introduction of Optive AI™ software provides a dramatic improvement in image quality, and we are excited about the opportunities for portable brain MRI with the Swoop® system across the UK," added Dr. Joanne Rodda, consultant psychiatrist and researcher at Kent and Medway NHS Trust and Social Care Partnership Trust.

    "Optive AI™ software delivers a substantial improvement in image quality, which improves diagnostic confidence and enables broader use in a variety of clinical settings. We are excited to bring these advancements to clinicians and patients in the EEA and UK to drive global adoption of our Swoop® system," said Maria Sainz, President and Chief Executive Officer of Hyperfine, Inc. "These approvals underscore our commitment to operational excellence and global expansion, and achieving them so quickly after our US FDA clearance is a testament to the strength of our regulatory and product teams."

    For more information about the Swoop® system, please visit HyperfineMRI.com.

    About the Swoop® Portable MRI Systems

    The Swoop® Portable MR Imaging® Systems are U.S. Food and Drug Administration (FDA) cleared for brain imaging of patients of all ages. They are portable, ultra-low-field magnetic resonance imaging devices for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis.

    About Hyperfine, Inc.

    Hyperfine, Inc. (NASDAQ:HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop® system—the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. For more information, visit HyperfineMRI.com.

    The Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc. The Swoop logo, Optive AI logo, and Optive AI are trademarks of Hyperfine, Inc.

    Forward-Looking Statements

    This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the "Company") may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's goals and commercial plans, the benefits of the Company's products and services, and the Company's future performance and its ability to implement its strategy. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company's product development and commercialization activities, including the degree that the Swoop® system is accepted and used by healthcare professionals; the impact of COVID-19 on the Company's business; the inability to maintain the listing of the Company's Class A common stock on the Nasdaq; the Company's inability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company's products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company's products and services and reimbursement for medical procedures conducted using the Company's products and services; the Company's estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties indicated from time to time in Company's filings with the Securities and Exchange Commission, including those under "Risk Factors" therein. The Company cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250902202329/en/

    Media Contact

    Devin Zell

    Hyperfine

    [email protected]



    Investor Contact

    Webb Campbell

    Gilmartin Group LLC

    [email protected]

    Get the next $HYPR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HYPR

    DatePrice TargetRatingAnalyst
    8/11/2022$8.00 → $2.40Overweight → Equal Weight
    Wells Fargo
    5/31/2022$7.00Outperform
    Evercore ISI
    4/14/2022$8.00Overweight
    Wells Fargo
    More analyst ratings

    $HYPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Teisseyre Thomas sold $1,531 worth of shares (1,151 units at $1.33), decreasing direct ownership by 0.30% to 381,062 units (SEC Form 4)

    4 - Hyperfine, Inc. (0001833769) (Issuer)

    8/18/25 4:10:40 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Director Wolterman Dan

    4 - Hyperfine, Inc. (0001833769) (Issuer)

    6/6/25 4:01:04 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CFO and CAO Hale Brett was granted 300,000 shares (SEC Form 4)

    4 - Hyperfine, Inc. (0001833769) (Issuer)

    5/20/25 5:26:31 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HYPR
    SEC Filings

    View All

    SEC Form 424B5 filed by Hyperfine Inc.

    424B5 - Hyperfine, Inc. (0001833769) (Filer)

    10/16/25 4:20:49 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 8-K filed by Hyperfine Inc.

    8-K - Hyperfine, Inc. (0001833769) (Filer)

    10/16/25 4:18:17 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 424B5 filed by Hyperfine Inc.

    424B5 - Hyperfine, Inc. (0001833769) (Filer)

    10/15/25 4:33:42 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HYPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hyperfine Announces First Patients Enrolled in PRISM PMR to Evaluate the Use of Next-Generation Swoop® System in the Operating Room Setting

    With several patients already enrolled in the study, PRISM PMR is designed to evaluate the Swoop® system's clinical utility in the operating room. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced plans for clinical use expansion into the operating room environment, advancing its mission to make brain MRI more accessible across a diversity of care settings. The company plans to establish a foothold in the neurosurgical operating setting by launching a new study to build a body of clinical evidence for Swoop® system use in neur

    10/21/25 8:15:00 AM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Hyperfine Announces Pricing of $17.5 Million Public Offering

    Hyperfine, Inc. (NASDAQ:HYPR) ("Hyperfine" or the "Company") today announced it has priced its previously announced underwritten public offering of 14,000,000 shares of the Company's Class A common stock at a public offering price of $1.25 per share. All of the shares in the offering are being sold by Hyperfine. In addition, Hyperfine has granted the underwriter a 30-day option to purchase up to 2,100,000 shares of Class A common stock, which equals 15% of the total number of shares of Class A common stock to be sold in the offering, at the public offering price, less underwriting discounts and commissions. The gross proceeds to Hyperfine from the offering are expected to be approximately $

    10/16/25 8:00:00 AM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Hyperfine Announces Proposed Public Offering

    Hyperfine, Inc. (NASDAQ:HYPR) ("Hyperfine" or the "Company") today announced that it has commenced an underwritten public offering of its Class A common stock or, in lieu of Class A common stock to certain investors, pre-funded warrants to purchase Class A common stock. All securities to be sold in the offering will be sold by Hyperfine. In addition, Hyperfine intends to grant the underwriters a 30-day option to purchase up to 15% of the total number of securities sold in the offering (consisting of shares of Class A common stock, pre-funded warrants or any combination thereof), on the same terms and conditions. The offering is subject to market and other conditions, and there can be no ass

    10/15/25 4:06:00 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HYPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Hyperfine downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Hyperfine from Overweight to Equal Weight and set a new price target of $2.40 from $8.00 previously

    8/11/22 6:32:27 AM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Evercore ISI initiated coverage on Hyperfine with a new price target

    Evercore ISI initiated coverage of Hyperfine with a rating of Outperform and set a new price target of $7.00

    5/31/22 7:16:51 AM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Wells Fargo initiated coverage on Hyperfine with a new price target

    Wells Fargo initiated coverage of Hyperfine with a rating of Overweight and set a new price target of $8.00

    4/14/22 7:32:25 AM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HYPR
    Leadership Updates

    Live Leadership Updates

    View All

    QuidelOrtho Announces Appointment of Two Independent Directors to its Board

    Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T

    12/10/24 7:00:00 AM ET
    $CTLT
    $HYPR
    $NVST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    Hyperfine Announces Strategic Leadership Additions to Drive Growth in Key Business Verticals

    Two new executive roles position Hyperfine to drive the adoption of the Swoop® system in hospital settings and expand into the office setting, laying the foundation for significant growth in 2025 and beyond. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced the appointment of Chi Nguyen as Vice President of Office Strategy and Partnerships and Rafael Donnay as Vice President of Hospital Strategy and Health Economics to provide leadership in key growth areas. These strategic leadership appointments bolster t

    12/3/24 9:00:00 AM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Hyperfine, Inc. Continues Global Market Expansion by Entering Into a Distribution Partnership with Radiosurgery Global, Ltd. to Bring the Swoop® System to India

    Strategic focus on India aims to make the Swoop® portable MR brain imaging system commercially available in a vast and underserved MRI market Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced it has entered into a distribution agreement with Radiosurgery Global, Ltd. to develop the market in India. The distribution agreement also includes the countries of Malaysia, Indonesia, and Singapore through future expansion, offering Hyperfine, Inc. a significantly increased presence in Asia. The clinical value of the Swoop®

    5/28/24 9:00:00 AM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HYPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Hyperfine Inc.

    SC 13G - Hyperfine, Inc. (0001833769) (Subject)

    2/13/24 5:06:19 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Hyperfine Inc. (Amendment)

    SC 13G/A - Hyperfine, Inc. (0001833769) (Subject)

    2/14/23 4:07:09 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Hyperfine Inc. (Amendment)

    SC 13G/A - Hyperfine, Inc. (0001833769) (Subject)

    12/20/22 4:22:37 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HYPR
    Financials

    Live finance-specific insights

    View All

    Hyperfine, Inc. Reports Second Quarter 2025 Financial Results

    GUILFORD, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced second quarter 2025 financial results and provided a business update. "In the second quarter, we executed across our key growth drivers. We received FDA clearances for our latest software, Optive AITM, and for the next generation Swoop® system powered by Optive AITM software, which represent a key inflection point in our technology. We also completed our pilot neurology office program. We believe these criti

    8/13/25 4:05:00 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Hyperfine, Inc. to Announce Second Quarter 2025 Financial Results on August 13, 2025

    Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced that it will report financial results for the second quarter 2025 on Wednesday, August 13, 2025. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. About the Swoo

    7/30/25 4:05:00 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Hyperfine, Inc. to Announce First Quarter 2025 Financial Results on May 13, 2025

    Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the first quarter 2025 on Tuesday, May 13, 2025. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. About the Swo

    4/29/25 4:28:00 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care